FDA expresses concern over vinpocetine supplements and fetal risks

The U.S. Food and Drug Administration is expressing concern regarding supplements containing vinpocetine, a derivative of the lesser periwinkle plant. The National Institute of Health’s National Toxicology Program has linked vinpocetine consumption to miscarriage and harm to fetal development. Studies on pregnant animals also concluded that vinpocetine decreased fetal weight and increased the chances of a miscarriage. The FDA is advising pregnant women and women who could become pregnant not to purchase or take these supplements.

The regulatory concern impacts the supplement market, which is valued at $35 billion. The FDA's advisory regarding vinpocetine supplements could affect consumer demand within this large industry.